Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...

Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty ...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...

XYNGARI� Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America - SAN DIEGO, March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, ...

“Without that, you basically don’t have a mechanism for paying for these vaccines, and so it’s a much larger issue than just telling parents that this is a good thing to do,” Osterholm ...

Join Dr. Dustin, a board-certified dermatologist, as he delves into how birth control pills can effectively treat acne. This video elucidates the mechanisms behind birth control's impact, such as ...

It is also useful in treatments for acne, hyperpigmentation, and the visible signs of aging. However, as with all chemical exfoliants, using glycolic acid too frequently, at too high a ...

Detailed price information for Dermata Therapeutics Inc WT (DRMAW-Q) from The Globe and Mail including charting and trades.